Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study

  • Shigetoshi Sano, Hiroshi Kubo, Hitomi Morishima, Ryosuke Goto, Richuan Zheng, Hidemi Nakagawa
  • The Journal of Dermatology, March 2018, Wiley
  • DOI: 10.1111/1346-8138.14294

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1111/1346-8138.14294

The following have contributed to this page: Dr Hiroshi Kubo